Treatment and secondary prevention of venous thromboembolic complications: positions of apixaban
- Authors: Vorobyeva N.M.1, Tkacheva O.N.1
-
Affiliations:
- Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University
- Issue: Vol 30, No 9/10 (2023)
- Pages: 110-114
- Section: Cardiology
- URL: https://journals.eco-vector.com/2073-4034/article/view/624909
- DOI: https://doi.org/10.18565/pharmateca.2023.9-10.110-114
- ID: 624909
Cite item
Open Access
Access granted
Abstract
The review discusses the possibilities of using the direct-acting oral anticoagulant apixaban for the treatment and secondary prevention of venous thromboembolic complications (VTEC). The results of randomized clinical trials (RCTs), meta-analyses of RCTs and real-world clinical practice studies demonstrate a favorable efficacy and safety profile of apixaban for the treatment and secondary prevention of VTEC, incl. in patients with malignant neoplasms, who are characterized by a high risk of not only thrombosis, but also bleeding. For all patients with VTEC, apixaban is safer than standard therapy with enoxaparin/warfarin, because the risk of major bleeding associated with its use is lower by 69%, and in patients with active cancer, the safety of apixaban is not inferior to that of standard treatment. An important advantage of apixaban is the absence of an increase in the frequency of gastrointestinal bleeding in patients with cancer-associated thrombosis.
Full Text
About the authors
N. M. Vorobyeva
Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University
Author for correspondence.
Email: natalyavorobjeva@mail.ru
ORCID iD: 0000-0002-6021-7864
Dr. Sci. (Med.), Senior Researcher at the Laboratory of Clinical Pharmacology and Pharmacotherapy
Russian Federation, MoscowO. N. Tkacheva
Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University
Email: natalyavorobjeva@mail.ru
ORCID iD: 0000-0002-4193-688X
Russian Federation, Moscow
References
- Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–46. doi: 10.1016/S0140-6736(11)61904-1.
- Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl. 2):e419S–96. doi: 10.1378/chest.11-2301.
- Konstantinides S.V., Torbicki A., Agnelli G., et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69, 3069a–3069k. doi: 10.1093/eurheartj/ehu283.
- Agnelli G., Buller H.R., Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. doi: 10.1056/NEJMoa1302507.
- Agnelli G., Buller H.R., Cohen A., et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. doi: 10.1056/NEJMoa1207541.
- Cohen A.T., Hamilton M., Mitchell S.A., et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One. 2015;10(12):e0144856. doi: 10.1371/journal.pone.0144856.
- Dawwas G.K., Leonard C.E., Lewis J.D., Cuker A. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med. 2022;175(1):20–8. doi: 10.7326/M21-0717.
- Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13(12):2187–91. doi: 10.1111/jth.13153.
- McBane R.D., Wysokinski W.E., Le-Rademacher J.G., et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–21. doi: 10.1111/jth.14662.
- Agnelli G., Becattini C., Meyer G., et al.; Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599–607. doi: 10.1056/NEJMoa1915103.
- Giustozzi M., Agnelli G., Del Toro-Cervera J., et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. J Thromb Haemost. 2020;120(7):1128–36. doi: 10.1055/s-0040-1712098.
- Frere C., Farge D., Schrag D., et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2022;15(1):69. doi: 10.1186/s13045-022-01289-1.
- Carrier M., Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol. 2017;10(1):15–22. doi: 10.1080/17474086.2017.1257935.
- Farge D., Frere C., Connors J.M., et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–47. doi: 10.1016/S1470-2045(22)00160-7.
Supplementary files
